Estimation application downloads and cost
Description
The Prostate Cancer Clinical Risk Classification app allows healthcare professionals to input clinical values to return a Prostate Cancer Risk Group Classification (Very Low, Low, Intermediate, High, Very High), based on the NCCN® Clinical Practice Guidelines Version 3.2016. You will answer up to 6 questions about your patient with localized (N0 M0) prostate cancer to generate an anonymous NCCN® Risk Group Classification. No patient information is stored locally or remotely.
Clinical parameters include:
* Gleason Score
* PSA Level
* Clinical T-Stage
* # of Positive Cores
* Total % tumor involvement in any core
* # cores with 4+3
* PSA Density
The result screen prominently displays the NCCN® Risk Group, as well as a summary of the values that were entered. The results will also indicate whether a patient with the entered clinical parameters would be eligible for the Oncotype DX® test. The Oncotype DX® Genomic Prostate Score is a biopsy-based gene expression test that predicts the biologic aggressiveness of disease in men with clinically low-risk prostate cancer. The Oncotype DX Genomic Prostate Score refines risk stratification, providing critical information for urologists and patients to confidently choose Active Surveillance or immediate treatment.
The Prostate Cancer Clinical Risk Classification app is supported by Genomic Health, Inc. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.3.2016.
For more information on the Oncotype DX® Genomic Prostate Score, visit www.oncotypedx.com.
Read more
Clinical parameters include:
* Gleason Score
* PSA Level
* Clinical T-Stage
* # of Positive Cores
* Total % tumor involvement in any core
* # cores with 4+3
* PSA Density
The result screen prominently displays the NCCN® Risk Group, as well as a summary of the values that were entered. The results will also indicate whether a patient with the entered clinical parameters would be eligible for the Oncotype DX® test. The Oncotype DX® Genomic Prostate Score is a biopsy-based gene expression test that predicts the biologic aggressiveness of disease in men with clinically low-risk prostate cancer. The Oncotype DX Genomic Prostate Score refines risk stratification, providing critical information for urologists and patients to confidently choose Active Surveillance or immediate treatment.
The Prostate Cancer Clinical Risk Classification app is supported by Genomic Health, Inc. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Guideline Name V.3.2016.
For more information on the Oncotype DX® Genomic Prostate Score, visit www.oncotypedx.com.
Prostate Cancer Clinical Risk Classification Tool screenshorts
ASO analyse Prostate Cancer Clinical Risk Classification Tool app for iPhone and iPad
No search terms founded
Competitors of Prostate Cancer Clinical Risk Classification Tool application
Application availability
Available in countries
| Country | Price |
|---|---|
| USA | free |
Available for devices
iPhone3GS, iPhone4, iPodTouchFourthGen, iPad2Wifi, iPad23G, iPhone4S, iPadThirdGen, iPadThirdGen4G, iPhone5, iPodTouchFifthGen, iPadFourthGen, iPadFourthGen4G, iPadMini, iPadMini4G, iPhone5c, iPhone5s, iPadAir, iPadAirCellular, iPadMiniRetina, iPadMiniRetinaCellular, iPhone6, iPhone6Plus, iPadAir2, iPadAir2Cellular, iPadMini3, iPadMini3Cellular, iPodTouchSixthGen, iPhone6s, iPhone6sPlus, iPadMini4, iPadMini4Cellular, iPadPro, iPadProCellular, iPadPro97, iPadPro97Cellular, iPhoneSE, iPhone7, iPhone7Plus, iPad611, iPad612, iPad71, iPad72, iPad73, iPad74, iPhone8, iPhone8Plus, iPhoneX,Other apps from Genomic Health, Inc.
Similar apps
